Educational Forum

Oral contraceptives induced hepatotoxicity

B. Akshaya Srikanth a,*, V. Manisree b

ABSTRACT

Oral Contraceptives are the pharmacological agents used to prevent pregnancy. These are divided as the combined and progestogen methods and are administered orally, transdermally, systemically and via vaginal route. All these methods contain both oestrogen and progestogen. Vigorous usage of oral contraceptives and anabolic steroids as associated with cholestasis, vascular lesions and hepatic neoplasm. Benign hepatic neoplasms are clearly associated with oral contraceptives. In this article we discuss the various hepatocellular complications like cholestasis, benign neoplasm and hepatocellular carcinoma occurred by oral contraceptives.

Keywords: Oral contraceptives, Hepatotoxicity, Drug toxicity, Combined oral contraceptive pills, hepatic carcinoma, India

INTRODUCTION

Hepatotoxicity is caused by the xenobiotics that include prescribed and nonprescribed therapeutic agents including herbal medications, and vast array of other organic and inorganic substances that may be ingested deliberately or accidentally.1 Drug induced liver injury can be defined as a liver injury by drugs or herbal medicines leading to liver test abnormalities or liver dysfunction with reasonable exclusion of other etiologies.2 More than 900 drugs have been implicated in causing liver injury, chemicals often cause subclinical injury to the liver which manifests only as abnormal liver enzyme tests. Drug induced liver injury is responsible for 5 % of all hospital admissions and 50 % of all acute liver failures.3

Drug-induced liver injuries have an acute onset, develop while the medication is being administered, and manifest histological pattern that can be categorized as hepatocellular, cholestatic and mixed.4,5 Injury to the liver is largely defined by the increase in the blood level of proteins that are liberated from the damaged hepatocytes like alanine aminotransferase (ALT). The low level of the plasma proteins such as albumin and clotting factors synthesized by the liver or clinicopathologic evidence of impaired bile flow called cholestasis. For defining of the drug-induced liver disease requires histopathologic characterization rather than syndromic recognition of the liver test abnormalities.6

Contraception is defined as the prevention of conception, but generally it is understood to mean the intentional prevention of pregnancy. Oral Contraceptives are the pharmacological agents used to prevent pregnancy. Despite the high contraceptive prevalence, unintended pregnancy is common. About 30% of pregnancies which end in childbirth are unplanned when they are conceived.7

HORMONAL CONTRACEPTION

Hormonal methods of contraception can be divided into combined and progestogen-only methods.

Combined hormonal contraception

These are administered orally, transdermally, systemically and via the vaginal route. All the methods contain both oestrogen and progestogen. The oral dose of oestrogen in the combined oral contraceptive pills (COCP) varies from 50 to 15 µg and some contains mestranol. Most women now use the so-called low-dose pills containing 30-35µg. Lower dose pills are potentially safer since the cardiovascular risks of the pills are mainly due to oestrogen. The newest COCP in Indian market (Yasmin) contains a progestogen with both anti-androgenic and anti-mineralocorticoid activity (drospirenone). The pill is taken for 21 days followed by a 7-day break when withdrawal bleeding usually occurs. The routine use of the contraceptives associated with the increase of venous thrombosis. Increasing the use of pills together for three months (tricycling) or more likely associated with

*Correspondence to:
Dr. B. Akshaya Srikanth, Pharm.D
Email: akshaypharmd@gmail.com
amenorrhoea. This is particularly useful for women who experience symptoms associated with the withdrawal bleed such as dysmenorrhoea or menstrual migraine and for women on enzyme-induced drugs like anticonvulsants which theoretically reduce pill efficacy.

The principle mode of action of combined hormonal contraception (CHC) is the inhibition of ovulation. Oestrogen inhibits pituitary follicle-stimulating hormone (FSH) suppressing the development of the Luteinizing hormone (LH) surge. Pills are administered for 21 days followed by a 7-day hormone-free interval (HFI). Additional properties of the contraceptives changes in cervical mucus characteristics interfering with sperm transport a possible alteration in tubal motility, endometrial atrophy and impaired uterine receptivity.

**ORAL CONTRACEPTIVES INDUCED HEPATOTOXICITY**

Oral contraceptives and anabolic steroids as associated with cholestasis, vascular lesions and hepatic neoplasm. Benign hepatic neoplasms are clearly associated with OCS.

**Cholestasis**

The frequency of cholestasis with OCS is 2.5 per 10,000 women exposed. Individuals with a previous history of the cholestasis of pregnancy are also at risk (50%). Mild prodromal symptoms such as anorexia and nausea, followed pruritus, develop 2 to 3 months after starting OCS. SAP level is moderately elevated and development of the chronic cholestasis is extremely a rare occurrence, generally recover within the days to weeks after drug cessation. Hormone replacement therapy (HRT) is safe in patients with liver diseases, but not recommended to jaundiced patients as the increase in bilirubin levels. So, it’s necessary to monitor with liver tests.

**Benign neoplasm**

OCS can induce enlargement of the preexisting hemangiomas through their trophic effect on the vascular endothelium. Recurrences of the hemangiomas have also seen in patients with a history of previous resected lesions. A role for the estrogens in the pathogenesis of FNH is possible because these lesions occur principally in young women (86%). In some cases liver adenomas are associated with the use of OCS. A study of over 200 patients with FNH failed to show a relationship between OCS and number of FNH lesions. The association between OCS and the hepatic adenomas was described approximately 30 years ago. In 1970s the increasing frequency of the neoplasm has been raised with OCS use. The long-term OCS users (>10 years) has the risk of 100-fold of benign neoplasms. Patients with adenomas usually regress after OCSS are withdrawn, but surgery is required to avert possible rupture and has a definite risk of malignant transformation. To prevent adenomas, OCSs with lower estrogenic potency are recommended.

**Hepatocellular carcinoma (HCC)**

The relative risk of HCC increases with twofold among women taking OCS and has a increasing risk of sevenfold in long term users compared to age matched control. But the estrogen-related HCC is rare and less than 2% of primary liver cancer observed in western countries. In context, OCS is not an independent cause of the HCC as far importance with the chronic viral hepatitis.

**CONCLUSION**

Chronic use of oral contraceptives is associated with the development of hepatic adenomas, benign tumors typically observed only in women of childbearing age and these can be resolved completely with drug withdrawal, and development of the risk factors depends upon the duration of the drug exposure. Hepatocellular carcinomas have been associated with the chronic use of anabolic, androgenic, and contraceptive steroids. Intensive researches are needed on contraceptives about the underlying mechanism of these agents produce tumors, malignancy tumors and benign adenomas. Oral contraceptives can also cause peliosis hepatis, in which weakening of sinusoidal membrane leads to the development of blood-filled sacs within the hepatic parenchyma.

**REFERENCES**


Cite this article as: Srikanth BA, Manisree V. Oral contraceptives induced hepatotoxicity. Int J Basic Clin Pharmacol 2013;2:91-3.